Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Ildong Holdings Co., Ltd., established in Seoul, South Korea, in 1941, operates internationally, specializing in the innovation, production, and supply of pharmaceutical goods. The company actively researches and develops novel therapeutics for challenging conditions such as resistant bacteria, various cancers, Alzheimer's disease, obesity, and age-related ailments. Its product portfolio encompasses fundamental ingredients like raw vitamins, probiotics, and antimicrobials, alongside prominent brands such as the lactobacillus product Biovita and the multivitamin Aronamin. Beyond pharmaceuticals, Ildong Holdings is involved in creating and manufacturing health foods and their components. It provides hyaluronic acid for applications in medicine, medical devices, and cosmetics, and offers a range of medical devices designed for aesthetic, plastic surgery, and anti-aging treatments. The company also facilitates online sales of an extensive array of healthcare-related products, including medical equipment, over-the-counter medicines, dietary supplements, food, beverages, cosmetics, and sanitary items. Furthermore, Ildong Holdings delivers beauty and cosmetic surgery services, along with pharmaceutical system integration (SI) consulting, system design and implementation, RFID and barcode solutions, and other specialized services, in addition to an advertising division. The entity adopted its current name, Ildong Holdings Co., Ltd., in August 2016, having previously operated as Ildong Pharmaceutical Co., Ltd.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITD